Catalog Advanced Search
Clinical Hepatology Update Conference 2019Contains 26 Component(s) Recorded On: 06/14/2019
Addressing Gaps in the Current Guidance: Assessing DILI with Novel Treatments or Preexisting Liver Disease in Clinical Trials
** VIEW ONLY CONTENT. The Clinical Hepatology Update 2019 enduring course will be available soon. It will be available under the "On-Demand Accredited Activities". **
The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.
• Patient Care and Procedural Skills
• Provide Patient-centered Care
• Values/Ethics for Interprofessional Practice
• Medical Knowledge
• Work in Interdisciplinary Teams
• Practice-based Learning and Improvement
• Employ Evidence-based Practice
• Interprofessional Communication
• Interpersonal and Communication Skills
• Apply Quality Improvement
• Teams and Teamwork
• Systems-based Practice
Lisa Catalli, MSN, NP-B
Elizabeth K. Goacher, PA-C, MHS
Janice Jou, MD, MHS
Marcelo Kugelmas, MD, FAASLD
- To understand and describe the current standard of care for the diagnosis and management of non-alcoholic fatty liver disease.
- Manage patients with complications of portal hypertension.
- Recognize when decompensated cirrhosis patients are appropriate candidates for palliative care and hospice referral.
- Nurse Practitioners
- Physician Assistants
- Transplant Coordinators
HCV Treatment in Patients with IDUContains 2 Component(s) Recorded On: 05/21/2019
Webinar hosted by the Hepatitis C Special Interest Group on May 21, 2019.
Injection Drug Use (IDU) remains the leading risk factor for HCV. Unfortunately, significant obstacles limit every aspect of the HCV care cascade in this population. This webinar will address the unique aspect of HCV and IDU and offer strategies to overcome existing limitations. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.
Jennifer Price is an Associate Professor in the Department of Medicine and Division of Gastroenterology and Hepatology at the University of California, San Francisco (UCSF) and the Director of the UCSF Viral Hepatitis Center. Dr. Price leads the UCSF HCV Project Extension for Community Healthcare Outcomes (ECHO), a collaborative model of medical education and care management focused on building capacity for HCV care among primary care providers throughout Northern California. She launched UCSF’s first mobile liver clinical care unit, the DeLIVER Care Van, which aims to improve access to HCV screening and high-quality liver-related health care among medically and geographically marginalized communities.
Stacey Trooskin, MD PhD, is the Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers and Clinical Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. She received her MPH from Yale University School of Public Health, her medical degree from Robert Wood Johnson Medical School, and her PhD from Rutgers School of Public Health. She completed her internal medicine residency and infectious diseases fellowship at the Hospital of the University of Pennsylvania.
Dr. Trooskin’s primary research interest focuses on health disparities and developing and evaluating innovative models of HCV testing and linkage to care. Dr. Trooskin serves at the Chief Medical Advisor to the National Viral Hepatitis Roundtable and is a member of the AASLD/IDSA HCV Guidelines Committee. She is the Community Co-chair of the Hepatitis C Allies of Philadelphia (HepCAP) and the Principal Investigator of C Change: Philadelphia’s Plan to End Hepatitis C Among People Who Inject Drugs.
Dr. Alain Litwin is Vice Chair of Academics and Research and Professor of Medicine at Prisma Health, University of South Carolina School of Medicine – Greenville, and Clemson University School of Health Research where he leads a Center for Addiction and Prevention Research. He is board certified in internal medicine and addiction medicine and has been providing medical care to people who use drugs with complex social, psychiatric and medical needs within an integrated primary care and substance use treatment program since 2000.
As HCV Medical Director at Albert Einstein’s Division of Substance Abuse, he developed a comprehensive on-site HCV treatment program and peer educator program to improve medical care of HCV-infected people who use drugs. As HCV Treatment Network Director at Montefiore Medical Center, he expanded patient-centered models of care at many community health centers serving thousands of HCV-infected people throughout the Bronx. With funding from NIH, PCORI, CMS, CDC, AHRQ, Robert Wood Johnson Foundation, New York State Department of Health, New York City Department of Health, and industry, Dr. Litwin’s research has been focused on developing and studying models of addiction and medical care for people who inject drugs (PWID), and on advocating for increasing access to effective care for all PWID.
Dr. Litwin has worked with government and community organizations on efforts to expand access to HCV treatment and has collaborated on policy statements, clinical guidelines, treatment improvement protocols, task forces, and educational curricula with diverse stakeholders. Dr. Litwin serves on the Executive Board for the International Network on Hepatitis in Substance Users (INHSU).
Management of NAFLD: Integrating Strategies from Obesity Medicine into Clinical PracticeContains 2 Component(s) Recorded On: 05/09/2019
Webinar hosted by the NAFLD Special Interest Group on May 9, 2019.
NAFLD is an increasing public health crisis. Although there are no FDA approved medications for the treatment of NAFLD, it is well established that weight loss can improve the metabolic and histologic parameters associated with NAFLD. This webinar will identify key lifestyle changes, pharmacotherapy, and the role of bariatric surgery in obesity management in patients with NAFLD. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.
Sonali Paul is a transplant hepatologist and Assistant Professor of Medicine at the University of Chicago. She is also the director of the Metabolic and Fatty Liver clinic. She has an interest in non-alcoholic fatty liver disease, obesity medicine, organ allocation, health disparities, and shared decision making between patients and providers. She received an MD from Tufts University School of Medicine. She completed her internal medicine residency at Massachusetts General Hospital and returned to Tufts for her fellowship training in gastroenterology. She also earned an MS in clinical and translational science from the Sackler School of Graduate Biomedical Sciences at Tufts University. She completed an advanced hepatology fellowship at Massachusetts General Hospital in 2016 and joined the University of Chicago faculty shortly thereafter.
Dr. Xanthakos is a Professor of Pediatrics within the Division of Gastroenterology, Hepatology and Nutrition at Cincinnati Children’s Hospital Medical Center, with clinical and research expertise in the management of pediatric obesity and nonalcoholic fatty liver disease. After receiving her MD degree from Duke University School of Medicine, she completed pediatric residency and fellowship training at Cincinnati Children’s. She serves as the director of the Steatohepatitis Center, as well as the medical director of the Surgical Weight Loss Program for Teens, one of the largest adolescent bariatric surgery programs in the United States. She also collaborates with colleagues from Cardiology, Endocrinology and Psychology in a multidisciplinary behavioral weight management program for children affected by multiple obesity-related comorbid conditions. She participates in several National Institute of Health-sponsored research consortia focused on children and adolescents with NAFLD and/or severe obesity, and also has received funding from the National Institutes of Health to investigate the outcomes of adolescents with NAFLD following bariatric surgery.
Liver Lesions 101Contains 2 Component(s) Recorded On: 04/25/2019
Webinar hosted by the Hepatology Associates Special Interest Group on April 25, 2019.
This session will cover principles of imaging characteristics of benign and malignant hepatic lesions. Attendees will also receive an overview of the Liver Imaging Reporting and Data System (LI-RADs) for imaging findings in liver lesions and common biomarkers associated with hepatocellular carcinoma. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.
Pediatric Liver Disorders SIG: Challenge of Fontan Associated Liver DiseaseContains 8 Component(s) Recorded On: 11/09/2018
AASLD's Pediatric Liver Disorders SIG: Challenge of Fontan Associated Liver Disease presented at The Liver Meeting® 2018.
The hemodynamic changes in Fontan circulation (the palliative intervention in single ventricle physiology) confer risk of liver complications, particularly congestive hepatopathy. This program will include descriptions of the hepatopathy, the pathobiology of Fontan associated liver fibrosis, available diagnostic tools including imaging techniques and transplant-related medical decision making in the context of a failing Fontan.
Career Development WorkshopContains 9 Component(s) Recorded On: 11/09/2018
AASLD's Career Development Workshop presented at The Liver Meeting® 2018.
This workshop will look at various training pathways for a career in hepatology. It will also describe various career opportunities in research, practice, education and industry, providing an overview of the rewards and challenges for each of these, and identify sources for research funding for fellows and junior faculty members.
Oren K. Fix
Emily Rothbaum Perito
Kathleen E. Corey
Lawrence S. Friedman
Dr. Lawrence S. Friedman attended Princeton University and received his undergraduate and medical degrees from the Johns Hopkins School of Medicine combined BA/MD program. He did his residency training at Johns Hopkins Hospital, followed by a clinical and research fellowship in gastroenterology at Harvard Medical School and Massachusetts General Hospital. He was on the faculty of Jefferson Medical College, where he served as Vice Chairman of the Department of Medicine and a member of the Gastrointestinal Unit at Massachusetts General Hospital. He is Professor of Medicine at Harvard Medical School and Tufts University School of Medicine. Since July 1, 2003, he has been Chair of the Department of Medicine at Newton-Wellesley Hospital and Assistant Chief of Medicine at Massachusetts General Hospital.
Mark W. Russo
Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized MedicineContains 7 Component(s) Recorded On: 11/09/2018
AASLD's Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized Medicine presented at The Liver Meeting® 2018.
This program will detail recent advances in the understanding of genetic and epigenetic alterations that influence NAFLD and its progression. It will emphasize their impact on the natural history of NAFLD and variability in clinical outcomes. Details on how patient based epigenetic association studies have led to novel insights into disease pathogenesis will be outlined with an emphasis on how this may translate to new therapeutics. Finally, the role of genetics and epigenetics in the evaluation of the patient in the clinic will be addressed – with particular reference to diagnosis, prognosis and therapeutics.
Liver Transplantation and Surgery SIG & Surgery and Liver Transplantation Cmte: Combined Organ TransplantsContains 11 Component(s) Recorded On: 11/10/2018
AASLD's Liver Transplantation and Surgery SIG & Surgery and Liver Transplantation Cmte: Combined Organ Transplants presented at The Liver Meeting® 2018.
This program will review the current status of liver transplantation in the setting of combined organ transplants (i.e., liver/intestine/multi-visceral, liver/ kidney, liver/heart and liver/lung transplantation). Indications, pathophysiology, operative management, post-transplant care and outcomes will be discussed in the context of specific extra-hepatic organ dysfunction and combined organ transplantation. The session will also address the immunologic, ethical, financial and operational issues associated with multi-organ transplant as well as integration of these combined organ transplants in the overall liver allocation framework.
Richard Shane Mangus
Patrick S. Kamath
Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology. At Northwestern, he completed a Master of Science in Clinical Investigation, is the Director of Liver Research, and is the program director for both Gastroenterology and Transplant Hepatology Fellowships. He has been elected to the Northwestern Feinberg Academy of Medical Educators and has received several teaching awards.
Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation and International Liver Transplantation Society where he served on the executive boards, as well as the AASLD where he has served on several committees. He is a Deputy Editor for the American Journal of Transplantation and on the Editorial Board for HEPATOLOGY. Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He previously received an AASLD Career Development Award in Liver Transplantation and has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. His goal is to advance clinical/translational research in immune-mediated liver diseases and liver transplantation, identifying biomarkers and novel strategies to optimize outcomes.
2018 Clinical Hepatology DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Clinical Hepatology Debrief presented at The Liver Meeting® 2018.
This session provides a summary of the clinical highlights from The Liver Meeting®.
Jorge A. Bezerra (Moderator)
K. Rajender Reddy
2018 Hepatitis DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Hepatitis Debrief presented at The Liver Meeting® 2018.
This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.
Jorge A. Bezerra (Moderator)
Jordan J. Feld